Trials
Search / Trial NCT06425393

Intrafamilial Helicobacter Pylori Infection in Hong Kong

Launched by CHINESE UNIVERSITY OF HONG KONG · May 20, 2024

Apply for Trial

Trial Information

Current as of March 14, 2025

Not yet recruiting

Keywords

H.Pylori Infection

ClinConnect Summary

Helicobacter pylori infects around half of the population in the world, and it is believed to affect more than half of population in Hong Kong. H. pylori infection is a well-known cause of chronic gastritis, peptic ulcer diseases and gastric cancer. Early detection and eradication of H. pylori infection is of utmost importance.

H. pylori infection is mainly transmitted by oral-oral, faecal-oral routes and water sources . Emerging studies demonstrated that intrafamilial spread is common. Recent national, family-based epidemiological study on H. pylori infection in mainland China showed a hi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Adults age\>=18 years of age
  • • For H. pylori infected patients only: Diagnosed to have H. pylori infection by either histology, rapid urease test or urea breath test
  • • Written informed consent obtained
  • Exclusion Criteria:
  • • Unable to perform urea breath test
  • • Contraindications for urea breath test
  • • Used antibiotics within the past month/proton pump inhibitors within two weeks

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0